Business
Aadi Bioscience Presents PRECISION 1 Trial in Progress Poster and AMPECT Trial Final Analysis at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting
Trial-in-progress poster showcases clinical trial design for PRECISION 1 and two additional posters demonstrate favorable durability of response and long-term
About this update from Whitehawk Therapeutics, Inc.
[{"type":"text","content":"Trial-in-progress poster showcases clinical trial design for PRECISION 1 and two additional posters demonstrate favorable durability of response and long-term safety of nab-sirolimus in the completed AMPECT study \nLOS ANGELES, Nov. 17, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today presented three posters on completed and ongoing clinical trials for nab-sirolimus at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting, taking place November 16-19, 2022 in Vancouver, Canada. nab-sirolimus (FYARRO®) is a novel mTOR inhibitor that leverages albumin-bound nanoparticle technology and is approved for the treatment of locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).\n\"We are thrilled to share more information from our AMPECT and PRECISION 1 trials with the leading sarcoma specialists from around the globe at CTOS 2022,\" said Loretta Itri, M.D., Chief Medical Officer of Aadi Bioscience. \"The trial-in-progress poster presents the design of our PRECISION 1 trial, while our two additional posters provide long-term analysis from our AMPECT trial that demonstrates nab-sirolimus' durability of response and long-term safety. We want to thank the CTOS organizers for the opportunity to showcase Aadi's clinical success and the patients who participated in these studies.\"\nDetails of the poster presentations are below:\nTitle: \"Phase 2, Multicenter, Open-Label Basket Trial of nab-Sirolimus for Patients with Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes (PRECISION 1)\"Date/Time: Thursday, November 17, 2022\nAadi and its collaborators present a trial-in-progress poster for PRECISION 1, a registrational-directed trial now recruiting for patients with solid tumors driven by TSC1/TSC2 alterations, an underserved patient population with no targeted therapeutic options.\nTitle: \"Study-end Analysis from AMPECT, an Open-Label, Phase 2 Registration Trial of Patients with Advanced Malignant PEComa Treated with nab-Sirolimus, Showing Durability of Responses and Long-Term Safety\"Date/Time: Thursday, November 17, 2022\nAadi and its collaborators present...